Prolia (Denosumab) Black / African Ancestry Documented Efficacy Gaps

Why the Evidence Gap Exists

Black and African ancestry individuals have been systematically underrepresented in osteoporosis clinical trials. This is not a minor footnote. It shapes everything clinicians can confidently say about denosumab efficacy in this population.

The FREEDOM Trial's Enrollment Problem

The landmark FREEDOM trial (N=7,868) randomized postmenopausal women with osteoporosis to denosumab 60 mg or placebo every 6 months for 36 months [1]. The study demonstrated a 68% reduction in vertebral fractures, a 40% reduction in hip fractures, and a 20% reduction in nonvertebral fractures. These numbers drive most prescribing decisions worldwide. The problem: the trial enrolled patients almost exclusively from Europe, Latin America, and Australia/New Zealand, with fewer than 2% of participants identified as non-White [1]. No race-stratified subgroup analysis for fracture endpoints was published from FREEDOM. The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis notes that "data on fracture outcomes in racial and ethnic minorities remain limited for most osteoporosis therapies" [2].

Downstream Effects on Guidelines

Because key trials lacked diversity, the National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) treatment thresholds were developed and validated primarily in White populations [3]. The FRAX fracture risk calculator includes a race/ethnicity adjustment for the United States, but this adjustment was built on epidemiologic fracture incidence data, not on treatment-response data from diverse trial cohorts [4]. Clinicians treating Black patients with denosumab are therefore extrapolating from trials that did not adequately test the drug in this group.

Baseline Bone Biology Differs by Ancestry

Understanding why efficacy data might differ requires understanding the biological starting point. Black individuals, on average, have measurably different skeletal characteristics compared to White individuals.

Higher Baseline Bone Mineral Density

Multiple large cohort studies confirm that Black Americans have 5% to 15% higher areal BMD at the hip and spine compared with White Americans of the same age and sex [5]. Data from NHANES III (N=14,646) showed that non-Hispanic Black women had femoral neck BMD approximately 12% higher than non-Hispanic White women after age adjustment [5]. This gap persists across the lifespan and is present in both sexes.

Lower Fracture Incidence Despite Similar Falls

Black women experience roughly half the hip fracture rate of White women at comparable ages [6]. A study published in the Journal of Bone and Mineral Research (N=2,127 fractures analyzed) found that age-adjusted hip fracture incidence in Black women was 1.7 per 1,000 person-years compared with 4.2 per 1,000 in White women [6]. This difference is not fully explained by BMD alone. Cortical bone geometry, trabecular microarchitecture, and muscle mass distribution all contribute to fracture resistance independent of DXA-measured density [7].

What This Means for Treatment Thresholds

A Black patient who meets DXA-based criteria for osteoporosis (T-score ≤ -2.5) may carry a different absolute fracture risk than a White patient at the same T-score. The FRAX algorithm partially accounts for this, producing lower 10-year fracture probability estimates for Black patients at the same BMD and age [4]. Whether denosumab provides the same relative risk reduction in fracture when the baseline absolute risk is lower remains unknown. No trial has been powered to answer this question.

Denosumab Pharmacology and Race

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast differentiation and activity [8]. Its mechanism is immunological, not metabolic. This distinction matters for pharmacogenomic considerations.

RANKL Biology Across Populations

RANKL is encoded by TNFSF11 on chromosome 13. Genome-wide association studies (GWAS) have identified variants in the TNFSF11 and TNFRSF11B (OPG) loci that influence BMD [9]. Some of these variants differ in allele frequency between populations of European and African ancestry. A 2012 meta-analysis of GWAS data from the GEFOS consortium (N=32,961) found that most BMD-associated loci had consistent effect directions across European and East Asian populations, but African ancestry cohorts were too small for reliable comparison [9]. The PharmGKB database lists no pharmacogenomic annotations linking TNFSF11 or TNFRSF11B variants to denosumab response in any population [10].

No Known Pharmacokinetic Differences

Denosumab is cleared through the reticuloendothelial system, not hepatic cytochrome P450 enzymes [8]. This means that CYP2D6, CYP2C19, and CYP3A4 polymorphisms, which show well-documented frequency differences between populations of African and European descent, do not affect denosumab metabolism. Body weight influences denosumab serum concentrations, but the approved 60 mg dose is not weight-adjusted [8]. Population pharmacokinetic modeling submitted to the FDA did not identify race as a significant covariate for denosumab exposure [11].

Vitamin D Status as a Modifier

Vitamin D deficiency is more prevalent in Black Americans, with NHANES data showing that approximately 72% of non-Hispanic Black adults have serum 25(OH)D levels below 20 ng/mL, compared with 30% of non-Hispanic White adults [12]. The Endocrine Society recommends correcting vitamin D deficiency before starting any antiresorptive therapy, including denosumab [2]. Whether lower baseline vitamin D status attenuates the BMD response to denosumab in Black patients has not been tested in a controlled study, but severe deficiency (<10 ng/mL) is associated with hypocalcemia risk during denosumab therapy in all populations [13].

Available Efficacy Data in Black Patients

The data that do exist come from subgroup analyses, post hoc evaluations, and observational registries. None were prospectively powered for the Black subgroup.

BMD Response Data

A pooled analysis of denosumab phase III trials (including FREEDOM and its extension) reported that BMD gains at the lumbar spine and total hip were consistent across age groups, baseline BMD categories, and geographic regions [14]. Race was not separately analyzed. In the denosumab arm of FREEDOM, lumbar spine BMD increased by 9.2% at 36 months compared with 0.2% in the placebo group [1]. Whether Black participants (who numbered in the low dozens within FREEDOM) showed the same, greater, or lesser response is not reported in published literature.

The ADAMO trial (N=228), which studied denosumab in men with low bone mass, enrolled a higher proportion of non-White participants (approximately 15%) but did not publish race-stratified BMD outcomes [15]. Dr. Michael McClung, director of the Oregon Osteoporosis Center, has noted: "We simply do not have the statistical power to make race-specific efficacy claims for denosumab. The trials were not designed for it" [16].

Fracture Reduction Extrapolation

Given the 68% relative risk reduction in vertebral fractures seen in FREEDOM [1], and assuming this relative reduction applies equally across racial groups, the absolute number of fractures prevented would be smaller in a population with lower baseline fracture incidence. For a 65-year-old Black woman with a FRAX-estimated 10-year major osteoporotic fracture probability of 8% (vs. 15% for a comparable White woman), the absolute benefit from treatment over 10 years would be roughly proportionally smaller. This is standard clinical reasoning for any treatment with relative risk reduction applied to varying baseline risk, but it has specific implications for cost-effectiveness analyses in diverse populations.

Real-World Observational Evidence

A retrospective cohort study using Medicare claims data (2012 to 2018) found that Black women prescribed denosumab had similar rates of medication persistence compared with White women at 12 months (approximately 55% vs. 58%) [17]. Fracture outcomes were not race-stratified. The study did note that Black women were significantly less likely to receive any osteoporosis pharmacotherapy after a fragility fracture, with treatment rates approximately 40% lower than in White women [17].

CKD, G6PD, and Population-Specific Safety Factors

Several comorbidities more prevalent in Black/African ancestry populations intersect with denosumab prescribing.

Chronic Kidney Disease

Black Americans have approximately 3.5 times the rate of end-stage kidney disease compared with White Americans [18]. Denosumab does not require renal dose adjustment since it is not renally cleared [8]. This makes it an attractive option in CKD stages 4 to 5, where bisphosphonates are contraindicated or require dose reduction. The KDIGO 2017 guidelines acknowledge denosumab as an option in CKD-MBD but warn about the risk of severe hypocalcemia in advanced CKD [19]. Post-marketing reports of hypocalcemia requiring hospitalization have been documented in patients with eGFR <30 mL/min [13].

G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10% to 14% of African American males [20]. There is no established interaction between denosumab and G6PD status. Denosumab is not an oxidative stressor, and G6PD status is not listed as a contraindication or precaution in the Prolia prescribing information [11]. This is worth noting because some patients and clinicians may have a general concern about drug safety in the context of G6PD deficiency. Based on available data, no screening for G6PD is needed before denosumab initiation.

Hypertension and Concurrent ACE Inhibitor/ARB Use

Hypertension prevalence is significantly higher in Black Americans (approximately 56% of adults vs. 48% overall) [21]. ACE inhibitors and ARBs, commonly used in this population, have no known pharmacologic interaction with denosumab [11]. There is no shared metabolic pathway or receptor target. Clinicians can prescribe denosumab alongside antihypertensive therapy without dose modification.

Clinical Recommendations for Black / African Ancestry Patients

Dr. Andrea Singer, clinical director of the Bone Health and Osteoporosis Foundation, has stated: "Treatment decisions for osteoporosis should be individualized based on fracture risk assessment, not deferred because of a patient's race. Higher average BMD in Black populations does not mean osteoporosis doesn't occur or that fractures aren't devastating when they do" [22].

When to Treat

Use FRAX with the "Black" ethnicity setting for US patients. Treat when the 10-year probability of major osteoporotic fracture exceeds 20% or hip fracture exceeds 3%, consistent with NOF/BHOF thresholds [3]. Do not dismiss low T-scores in Black patients as artifacts of population-level BMD differences. A Black patient with a T-score of -2.8 and a prior fragility fracture needs treatment.

Monitoring on Therapy

Standard monitoring applies: serum calcium and 25(OH)D before initiation, repeat DXA at 2 to 3 years, and clinical assessment for new fractures [2]. Ensure vitamin D repletion to at least 20 ng/mL (and ideally ≥30 ng/mL) before the first dose. In patients with CKD stage 4 to 5, monitor calcium weekly for the first month after each dose [19].

Discontinuation Risk

Rebound vertebral fractures after denosumab discontinuation have been documented across all studied populations [23]. There is no race-specific data on rebound risk. Current guidance from the American Society for Bone and Mineral Research recommends transitioning to a bisphosphonate (typically zoledronic acid) within 6 months of the last denosumab dose to mitigate rebound bone loss [23]. Apply this protocol regardless of patient ancestry.

The standard denosumab dose for osteoporosis remains 60 mg subcutaneous every 6 months for all racial and ethnic groups, with calcium 1,000 mg and vitamin D 400 to 800 IU daily supplementation [11].